abstract context: little is known about how the pharmaceutical industry responds to evidence of harm associated with its products, such as the publication in july 2002 of the women's health initiative estrogen plus progestin trial (whi e+p) report demonstrating that standard-dose prempro produced significant harm and lacked net benefits.